Status:
TERMINATED
Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
Lead Sponsor:
Centre Hospitalier Régional Metz-Thionville
Collaborating Sponsors:
University Hospital, Strasbourg, France
Centre Hospitalier de Verdun
Conditions:
Mite Allergy
Respiratory Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this clinical trial is to compare the positive predictive value of the combination rapid nasal provocation test (RNTP) + skin tests (TC) + specific immunoglobulins E (IgEs) to the combinati...
Detailed Description
Allergic rhinitis due to house dust mites (AAR) is a common condition which impairs the quality of life of patients and which can be responsible for complications such as the development of asthma. Th...
Eligibility Criteria
Inclusion
- Patient over 18 years old,
- Patient with persistent mild to severe or moderate to severe intermittent rhinitis according to ARIA criteria, suspicion of allergic rhinitis to dust mites, and a positive skin test for mites and / or a positive mite specific IgE assay
- Patient having signed a free and informed consent
Exclusion
- Pregnant or breastfeeding women
- Patients under guardianship or curatorship
- Patients under legal protection
- Patients not affiliated to a social security scheme
- Contraindications to performing a RNPT
- Active ENT or respiratory infections.
- Allergy in acute phase
- History of anaphylaxis due to the allergen involved.
- Unstabilized asthma and other obstructive pathologies.
- Severe general illnesses in evolution.
- Hypersensitivity to one of the components of the product
- Simultaneous treatment with beta-blockers or angiotensin-converting enzyme (ACE) inhibitors,
- Presence of an excessive degree of sensitization (e.g. history, excessive skin reactions),
- Contraindications to immunotherapy:
- Asthma (uncontrolled) or severe \[FEV \< 70% of the theorical value (after appropriate drug treatment) at the beginning of the treatment\].
- Severe asthma exacerbation in the last 3 months
- Active autoimmune diseases
- Malignant tumors
- Pregnancy (initiation of venereal disease)
- AIDS
- Treatment with beta-blockers, including eye drops
Key Trial Info
Start Date :
March 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 5 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04915352
Start Date
March 7 2022
End Date
July 5 2024
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHR Metz Thionville/Hopital de Mercy
Metz, Grand Est, France, 57085